HCPCS code J0715 – Ceftizoxime sodium injection

Key takeaways

CMS deleted HCPCS Code J0715 (injection, ceftizoxime sodium, per 500 mg) effective 31 December 2025, with no replacement code named

A claim line with J0715 and a date of service on or after 1 January 2026 denies as an invalid code

For 2026 dates of service, bill the unlisted-drug code J3490 with the drug name and NDC, unless the payer directs otherwise

Claims for dates on or before 31 December 2025 still bill J0715 at one unit per 500 mg given

Pabau’s claim validation checks claims for missing or invalid details before they go to the clearinghouse, and shows the reason when a claim is rejected.

HCPCS Code J0715: definition and deletion status

HCPCS Code J0715 was the HCPCS Level II code for injection, ceftizoxime sodium, per 500 mg.

CMS deleted it effective 31 December 2025, and the January 2026 discontinued-code list names no replacement code. It is not valid for any date of service on or after 1 January 2026.

The code sat in the J-series that the Centers for Medicare and Medicaid Services (CMS) keeps for drugs given other than by mouth. Practices reported it for the drug supply when ceftizoxime was given by IV infusion or IM injection. Claims for those services in 2025 or earlier still use it.

Ceftizoxime is a third-generation cephalosporin once sold as Cefizox. Its deletion took effect in the January 2026 annual update.

Is HCPCS Code J0715 still valid? The 31 December 2025 deletion

No. CMS discontinued J0715 in the January 2026 HCPCS update, with a termination date of 31 December 2025. The CGS Medicare January 2026 HCPCS update lists it among the discontinued codes, with the crosswalk column left blank. Noridian’s January 2026 update carries the same deletion.

The NLM HCPCS lookup, which carries the CMS code file, now flags J0715 as obsolete with a termination date of 31 December 2025. No grace period applies. A claim line with J0715 and a 2026 date of service is rejected as an invalid code.

Claims for services on or before 31 December 2025 still bill J0715, as long as they reach the payer within its timely filing limit. Medicare allows 12 months from the date of service, so late 2025 claims stay open until late 2026.

What to bill instead of J0715 from 1 January 2026

No HCPCS code currently describes ceftizoxime sodium. The CMS file holds no other ceftizoxime entry, so a 2026 dose falls to the unlisted-drug code J3490. Work through these five steps before the first 2026 claim goes out.

1. Confirm the drug that was given. If the patient received a different cephalosporin, bill that drug’s own code, such as J0696 for ceftriaxone. Never use an unlisted code when a specific one exists.
2. Check the payer’s instructions. Medicare contractors and most commercial payers take J3490 (unclassified drugs) for an injectable drug with no code of its own. J3490 is active in the current CMS file.
3. Report the drug details. Put the drug name, dose and route in the narrative field: item 19 on the CMS-1500, or loop 2400 NTE on the 837P. Add the 11-digit NDC as well.
4. Expect manual pricing. J3490 carries no fixed payment limit, so the contractor prices the line from the invoice or the NDC. Keep the purchase invoice on file.
5. Retire J0715 in your systems. Remove it from the charge master and fee schedule, so no 2026 encounter can pick it up by default.

Some Medicaid programs and commercial plans publish their own unlisted-drug rules. Check the plan policy before the first claim, because a rejected J3490 line usually comes down to missing drug details. The diagram below maps each ceftizoxime dose to its code by date of service.

Billing units for J0715 claims dated on or before 31 December 2025

This section applies only to claims for services on or before 31 December 2025. Each unit of J0715 represents 500 mg of ceftizoxime sodium given. Divide the total dose in milligrams by 500 to get the unit count.

CMS Medically Unlikely Edits (MUEs) cap the units allowed per claim line per day. Check the MUE value that was in force on the date of service, not today’s table. A line above the MUE denies, and an appeal needs the administration record.

NDC reporting for ceftizoxime claims

Most payers require a National Drug Code (NDC) on every drug claim line. That covers J0715 lines dated in 2025 or earlier, and J3490 lines for 2026 doses. When submitting a clean claim, the NDC ties the code to the exact product, labeler and package that was used.

NDC format and claim placement

Claims take the NDC in an 11-digit format. Convert the FDA’s 10-digit format by adding a leading zero to the labeler, product or package segment as needed. Report it in these places:

• CMS-1500 paper claims: Box 24A, shaded area, using qualifier N4, the 11-digit NDC, the unit qualifier (UN, GR or ML) and the quantity
• 837P electronic transactions: Loop 2410, segment LIN (N4 qualifier and 11-digit NDC) and segment CTP (quantity and unit of measure)
• Outpatient facility UB-04: Form locator 43 on the drug’s revenue code line, following payer-specific instructions

Take the NDC from the label of the vial that was used, not from a database. A mismatched NDC is a compliance risk as well as a denial trigger. The FDA National Drug Code Directory confirms the format and labeler.

Medicare reimbursement for J0715: ASP and payment methodology

For dates of service through 31 December 2025, Medicare Part B paid J0715 in the physician office at Average Sales Price (ASP) plus 6 percent. The payment limit came from the quarterly file on the CMS ASP drug pricing files page. Use the file for the quarter that holds the date of service.

Where manufacturers reported no ASP data, CMS could price a code from Wholesale Acquisition Cost (WAC) or leave it to the contractor. From 2026, ceftizoxime billed under J3490 has no ASP payment limit, so the MAC prices each line individually.

Drug administration codes to bill alongside J0715

J0715 covered the drug supply only. The infusion or injection is a separate CPT administration code on the same claim. That pairing still applies when the drug bills under J3490 in 2026.

Physician offices report the administration code on the professional claim. Hospital outpatient departments also report codes such as 96365 and 96372 on the facility claim. OPPS then decides whether each line is paid separately or packaged.

Leaving out the administration code, or using the wrong one, is a common source of NCCI edit denials. The superbill documentation for a J0715 encounter should capture both the drug code and the administration CPT.

Comparable and related HCPCS drug codes for J0715

Ceftizoxime is one of several injectable cephalosporins with HCPCS J-codes. The others below are still active in the CMS file. If one of them was given, bill its own code, never J0715 or J3490.

The AAPC Codify HCPCS lookup lets you compare descriptors for neighboring J-codes side by side. J0694 and J0698 bill per gram, not per 500 mg. Applying J0715’s per-500 mg logic to them would double the units, turning 1 g into 2 units instead of 1, and overbill the claim.

Payer coverage and prior authorization for ceftizoxime claims

Medicare Part B generally does not require prior authorization for physician-administered antibiotics. Each Medicare Administrative Contractor (MAC) may still publish a Local Coverage Determination (LCD) listing covered diagnoses. For J3490 lines, contractors also use the drug name and NDC to judge coverage.

Commercial plans often require prior authorization for outpatient antibiotic infusion. Medicaid rules vary by state, and some programs need a formulary exception for an unlisted drug. Check the rules at the time of each service rather than relying on past claims.

• Medicare Part B: Generally no prior authorization; confirm covered diagnoses in your MAC’s LCD
• Commercial payers: Prior authorization is often required for outpatient infusion; check the plan policy
• Medicaid: State-dependent; an unlisted drug may need a formulary exception
• All payers: Documentation of the diagnosis and the indication for IV or IM therapy strengthens authorization requests and appeals

Common claim denial reasons for J0715 and how to resolve them

Most J0715 denials now fall into two groups: 2026 claims that still carry the deleted code, and late 2025 claims with unit or NDC errors. The table maps each cause to its usual CARC (Claim Adjustment Reason Code) and fix. Denial management workflows and medical billing fundamentals help billing teams triage them faster.

Reference the full list of common denial adjustment codes to map every CARC your practice receives to the right appeal strategy.

Documentation requirements for ceftizoxime claims

The line may bill J0715 for a 2025 date or J3490 for a 2026 date. Either way, the record must tie the drug to one patient, diagnosis and order. When the record skips one of those three, medical necessity and NDC denials tend to follow. The chart note or administration record needs each of these elements:

• Prescriber order: Drug name (ceftizoxime sodium), dose in milligrams, route (IV or IM) and frequency
• Administration record: Dose given, start and stop times for IV infusions, and the administering clinician’s signature
• Diagnosis: ICD-10-CM code(s) supporting the need for IV or IM antibiotic therapy
• NDC from the vial used: The NDC printed on the vial or lot label, not a database lookup value
• Drug description (J3490 only): Drug name, dose and route in the claim narrative, with the purchase invoice on file
• Prior authorization number: If the payer required authorization, the approval number must appear on the claim

When ceftizoxime was chosen because a preferred antibiotic was unsuitable, the chart note should say why. That detail supports medical necessity appeals and any formulary exception request.

How Pabau helps practices handle deleted HCPCS drug codes

A deleted drug code rarely fails loudly. The charge master keeps offering it, staff keep picking it, and the first sign is a run of CO-181 denials weeks later. Ranitidine injection’s HCPCS J2780, deleted on July 1, 2024 with no replacement, is another code that can linger in a charge master.

Pabau, the practice management platform we build, adds a check before the claim leaves. In Pabau’s claims software for practices, claim validation checks each claim for missing or invalid details before it goes to the clearinghouse. A claim flagged Needs action has a Fix button that links straight to the field that needs correcting.

When a claim is rejected, Pabau shows the reason so staff can fix it and resubmit. For a 2026 ceftizoxime line, that fix is usually swapping J0715 for J3490 or the code the payer names.

Keep deleted drug codes out of your claims

Pabau checks each claim for missing or invalid details before it reaches the clearinghouse, and shows the reason when one is rejected. See how it fits your drug billing.

Book a demo

Conclusion

J0715 is a closed code, but the claims around it are not. Late 2025 ceftizoxime claims still bill under it until the 12-month filing window closes. Every 2026 dose needs J3490 or the code the payer names.

Retire J0715 in the charge master once, and no 2026 encounter can pick it up by default. That one change saves a stack of CO-181 rework later. Book a demo to see how Pabau checks claims before they go out.

Continue your research

Need to understand how clearinghouse edits catch J-code errors before they reach the payer? Medical claims clearinghouse workflows explains how 837P edits are applied upstream of payer adjudication.

Want a framework for reducing claim denials across all billing codes? Clean claim submission standards covers the data elements payers validate on every professional claim.

Looking to understand the broader revenue cycle around drug injection billing? Revenue cycle management fundamentals maps the complete claim lifecycle from encounter to payment posting.

Frequently asked questions